Key Highlights
- Lisa Alderson appointed as CEO of Adela, Inc. for her extensive experience in healthcare and genomics, including roles at Genome Medical and Invitae.
- Alderson’s appointment follows successful leadership at Adela as interim CEO, demonstrating her capability in driving the company’s mission.
- Adela’s focus: Commercializing a groundbreaking blood test for minimal residual disease (MRD) monitoring and early cancer detection by 2025.
Source: PR Newswire
Notable Quotes
- “We are thrilled to appoint Ms. Alderson to lead Adela through its next phase of growth.” – David Scheer, Chairman at Adela’s Board of Directors
- “I’m excited to guide Adela through product development, commercialization, and growth with the goal of applying our innovative technology to advance patient care in oncology.” – Lisa Alderson, CEO at Adela
SoH's Take
Lisa Alderson’s appointment as CEO of Adela, Inc. marks a significant step in the company’s journey towards revolutionizing cancer care. Her extensive background in genomics and healthcare, coupled with her proven leadership skills, positions her ideally to steer Adela through the crucial stages of product development and commercialization. Alderson’s vision aligns seamlessly with Adela’s mission, emphasizing the importance of precision medicine in oncology. This move signals a promising future for Adela, as they gear up to introduce their innovative blood testing technology to the market. With a focus on minimal residual disease monitoring and early cancer detection, Adela is set to make a substantial impact on how cancer is diagnosed and managed, potentially improving outcomes for millions of patients worldwide.
